BRAF in primary and recurrent papillary thyroid cancers: The relationship with 131I and 2-[18F]fluoro-2-deoxy-D-glucose uptake ability

Susi Barollo, Gianmaria Pennelli, Federica Vianello, Sara Watutantrige Fernando, Isabella Negro, Isabella Merante Boschin, Maria Rosa Pelizzo, Massimo Rugge, Franco Mantero, Davide Nacamulli, Maria Elisa Girelli, Benedetto Busnardo, Caterina Mian

Research output: Contribution to journalArticle

Abstract

Objective: BRAF V600E is a potential marker of poor prognosis in papillary thyroid cancers (PTC). In a previous report, we showed that recurrent PTC with no radioiodine (131I) uptake are frequently associated with BRAF mutations, a low expression of thyroid-related genes and a high expression of glucose type-1 transporter gene. Aim: The aim of the present study was to assess BRAF status in a large series of recurrent PTC patients, considering paired primary and recurrent cancers. The BRAF genotype was correlated with the ability to concentrate 131I and/or 2-[18F]fluoro-2-deoxi-D- glucose (18F-FDG) in the recurrent cancers, serum markers of recurrence, and patient outcome. Design and methods: We studied 50 PTC patients with recurrent cervical disease submitted to a re-intervention, followed up in median for 9 years. BRAF analysis was conducted by direct sequencing and mutant allele-specific PCR amplification. In 18 cases, molecular analysis was also assessed in the primary cancer. Out of 50 patients, 30 underwent 18F-FDG-positron emission tomography - computed tomography. Results: BRAF V600E-positive recurrent patients were found 131I-negative in 94% of cases (P131I-negative and 18F-FDG positive. In paired primary and recurrent PTC, BRAF V600E was observed in 79% of the primary cancers and 84% of their recurrences. Three patients with 131I-negative and BRAF V600E-positive recurrent cancers deceased during follow-up. Conclusions: BRAF mutations are more common in thyroid recurrences with no 131I uptake than in 131I-positive cases. They are correlated with the ability to concentrate 18F-FDG, and they can appear, albeit rarely, as a de novo event in the course of PTC recurrences.

Original languageEnglish
Pages (from-to)659-663
Number of pages5
JournalEuropean Journal of Endocrinology
Volume163
Issue number4
DOIs
Publication statusPublished - Oct 1 2010

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Fingerprint Dive into the research topics of 'BRAF in primary and recurrent papillary thyroid cancers: The relationship with 131I and 2-[18F]fluoro-2-deoxy-D-glucose uptake ability'. Together they form a unique fingerprint.

  • Cite this

    Barollo, S., Pennelli, G., Vianello, F., Fernando, S. W., Negro, I., Boschin, I. M., Pelizzo, M. R., Rugge, M., Mantero, F., Nacamulli, D., Girelli, M. E., Busnardo, B., & Mian, C. (2010). BRAF in primary and recurrent papillary thyroid cancers: The relationship with 131I and 2-[18F]fluoro-2-deoxy-D-glucose uptake ability. European Journal of Endocrinology, 163(4), 659-663. https://doi.org/10.1530/EJE-10-0290